The Food and Drug Administration approved the first oral PCSK9 inhibitor on July 16, giving patients who need further LDL cholesterol reduction a daily pill option in a drug class that has been available only by injection.
Enlicitide, sold as Lipfendra, is a 20 milligram once-daily tablet approved as an adjunct to diet and exercise for adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia.
The question cardiologists are working through is placement rather than potency. The drug lowers LDL cholesterol substantially. Whether that translates into fewer heart attacks, strokes, and cardiovascular deaths is being tested in a trial that has not reported.
Two Mechanisms That Work Differently
Statins reduce the liver's production of cholesterol by inhibiting HMG-CoA reductase. As liver cholesterol falls, the liver increases LDL receptors on its surface and clears more LDL from the blood.
PCSK9 works on the other side of that process. It is a protein that binds LDL receptors and marks them for degradation, so fewer receptors survive to clear LDL. Blocking PCSK9 preserves those receptors, which is why the two drug classes combine well: statins increase receptor production, PCSK9 inhibitors keep the receptors in circulation longer.
Enlicitide is a macrocyclic peptide, a structural class that allowed a molecule large enough to block the PCSK9 interaction to survive oral administration. Existing PCSK9-pathway drugs are injectables, including evolocumab, alirocumab, and inclisiran, a small interfering RNA given twice yearly.
The Trial Numbers Behind the Approval
Approval rested on two phase 3 trials. CORALreef Lipids enrolled 2,904 adults with a history of a major atherosclerotic cardiovascular event or elevated risk of a first one, all of whom needed further LDL reduction alongside statin therapy.
At week 24, LDL cholesterol fell 57.1% with enlicitide and rose 3.0% with placebo, producing an adjusted between-group difference of 55.8 percentage points. Among those on enlicitide, 70.3% reached LDL below 70 milligrams per deciliter with at least a 50% reduction from baseline, compared with 1.5% on placebo, and 67.5% reached below 55 milligrams per deciliter with at least a 50% reduction, compared with 1.2%. Non-HDL cholesterol fell by an adjusted 53.4 percentage points, apolipoprotein B by 50.3, and lipoprotein(a) by a median 28.2.
CORALreef HeFH applied a similar design in patients with heterozygous familial hypercholesterolemia and produced a placebo-adjusted reduction of 59.4 percentage points, with effects apparent by week 4 and sustained through 52 weeks.
Safety and tolerability did not differ meaningfully between enlicitide and placebo in CORALreef Lipids, according to TCTMD.
The Surrogate Endpoint Problem
LDL cholesterol is a surrogate outcome. It is a laboratory value strongly associated with cardiovascular events, and lowering it with statins has repeatedly reduced those events, but the association is not automatic across every drug that lowers it.
Lipid medicine includes drugs that improved lipid panels without improving outcomes, and in some cases worsened them. That is why guideline writers distinguish LDL lowering from event reduction.
The test for enlicitide is CORALreef Outcomes, which has completed enrollment with more than 14,500 participants. Additional studies in the program include extension, pediatric, and combination trials.
The reason many cardiologists expect a benefit anyway is that PCSK9 inhibition through injectable drugs has already reduced cardiovascular events in outcome trials, and enlicitide acts on the same target through the same pathway. That is a reasonable inference. It is not the same as a result.
Where Clinicians See It Fitting
The population most discussed is people who need further LDL reduction on maximally tolerated statins and who either decline injections or face practical barriers to them.
Ann Marie Navar of UT Southwestern Medical Center, a lead author of the pivotal trial, described enlicitide as the most potent oral therapy available after high-intensity statins, and said an obvious patient group will be those unable or unwilling to take an injection. Jeffrey Berger of NYU Langone Health stressed to TCTMD that the approval adds a tool rather than replacing existing options.
The comparison against other oral non-statin options was tested separately. In the CORALreef AddOn trial of 301 statin-treated patients, enlicitide lowered LDL by 64.6% from baseline at eight weeks, with between-group differences of 56.7 percentage points versus bempedoic acid, 36.0 versus ezetimibe, and 28.1 versus the two combined. Adverse events and discontinuations were similar across groups. Lead author Alberico Catapano, who presented the results, framed the point in terms of choice, telling TCTMD that more options leave patients better off.
One practical detail deserves attention before a prescription is written. The tablet has specific administration requirements, including morning dosing on an empty stomach and a fasting period afterward, which makes counseling on routine and adherence more important than it would be for an ordinary daily pill.
Cost and coverage will shape access more than the pharmacology will. Injectable PCSK9 inhibitors faced years of prior authorization barriers after approval.
What Patients Should Do
Do not stop or reduce a statin. Statins have the deepest outcome evidence in cardiovascular prevention, and enlicitide is approved as an addition to diet and exercise, not as a statin replacement.
If you are on maximally tolerated statin therapy and your LDL remains above the target your clinician has set, this is a reasonable subject for your next visit. Bring your most recent lipid panel and ask what your target is and why.
If you are currently on an injectable PCSK9 inhibitor and it is working, there is no evidence-based reason to switch. Switching for convenience is a preference decision to make with your clinician, not an upgrade.
If you have stopped a lipid medication because of side effects, cost, or injection difficulty, say so directly. Those are common and there are now more options than there were a year ago.
People with familial hypercholesterolemia should ask about family screening. It is inherited, frequently undiagnosed, and identifying relatives changes their risk management.
Before starting any new medication, ask about interactions with what you already take, what monitoring is needed, how it must be taken, and what it will cost you after coverage.
Frequently Asked Questions
Is the oral PCSK9 inhibitor approved? Yes. The FDA approved enlicitide, sold as Lipfendra, on July 16, 2026, as a 20 milligram once-daily tablet.
How much does it lower LDL? In the pivotal trials, placebo-adjusted reductions were 55.8 percentage points in CORALreef Lipids and 59.4 percentage points in CORALreef HeFH.
Does it prevent heart attacks and strokes? That has not been shown. LDL reduction is a surrogate outcome. The CORALreef Outcomes trial, with more than 14,500 participants, has not been reported.
Does it replace statins? No. It is approved as an adjunct to diet and exercise and was studied in people already on statin therapy.
How does it differ from statins? Statins reduce cholesterol production. PCSK9 inhibitors preserve LDL receptors so the liver clears more LDL. The mechanisms are complementary.
Are there special instructions for taking it? Yes. It requires morning dosing on an empty stomach with a fasting period afterward, so ask your pharmacist how to fit it into your routine.
Should I switch from my injection? Not for its own sake. If your current therapy is working, discuss any change with your clinician rather than assuming an oral option is better.
